Member Info for inanaco

18 epitopes - all give T Cell response
from 5 different antigens

you can have multiple epitopes on one antigen ...

ok .... has the algorithm predicted the peptide sequence

something like Inovio use ... "syncon"

or has the algorithm been used to separate from others

Ray .... Lindy identifies the epitope on the cancer so 18 would be detected on the tumour ...

immune response ....

maybe in 4 have been tested ... ie they are immunogenic

i have not played it back to check,

i suspect its like citrulline 7 tested 40 discovered

lets wait the RNS .. otherwise some at the next AGM will bad mouth Lindy ... for failing to deliver 33 targets clinic ready

well that decision is Scancells C7 however SCIB2 could actually target metastatic melanoma

3.1. Melanoma-associated marker expression in primary and metastatic melanoma
The NY-ESO-1 stain was negative in all the primary melanomas and positive in 58 (28.2%) of the metastatic melanomas (Table 2).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946994/

Crumbs .. not sure linking 3 peptides to the adjuvant is difficult enough ... 5 ... ?

we don't know if Homocitrulline peptides requires the more difficult "hydrophobic" to be the most effective

but again building 2 vaccines rather than 1 super complex gives the program more versatility ... combinations may come into play, but in defined group ... established in trial

""" Vulpes Input may bring a sense of urgency """ on the contrary Vulpes due diligence was based on the last 12 months which is based on "getting a full understanding" .... "getting the science right" and getting the "right people involved" that was all done without Vulpes influence ... and indeed they may have a seat on the BOD but they don't have sufficient voting rights to change policy to ... "urgency" ... as that means an elevated Risk ... rather than a "cool head approach" .. If you feel the science should be pushed harder, exactly how would you achieve this ??? when so much time is eaten by regulatory requirements and getting the science written up for the patents ...

of which ""Diggles would be no help at all ""...

The value to scancell in developing in house is enormous because the IP is "improved" before any deal is agreed, this applies to BioNtech as well, as its Lindy that has stated its challenging, in other words Scancell input is far greater to solve process
the interesting bit is that they have a Moditope TCR operational .. however like the Mark One Modi1 .. Lindy was able to improve it to 100% of mouse survival ... in the Modi1 mark 2 ... with the addition of the adjuvant and hydrophobic peptides

Lindy puts the science first and gets it right ... before we embark on the expensive part ... "the Trials" its a pity many cannot see that and just feel we should "rush" moditope into the clinic when "commercial aspects" are best served with a 100% mouse model .. rather than 80%

Bermuda ... thought for you
Moditope and MRna ...

If lindy felt that an Mrna vaccine was the more efficient route to market they would have deployed immunobody to deliver the moditope peptides as Immunobody and MRNA have very similar outcomes ...

the adjuvant from ISA Pharma thou really fine tunes the differentiation of the CD4 killer cell making it highly inflammatory ...

on Immunobody the adjuvant is the actual electric shock which creates cytokines around the injection site ...

but MRNA and immunobody are very similar approaches

Cancer immunotherapy has been proposed as a powerful treatment modality. Active immunotherapy aspires to stimulate the patient's immune system, particularly T cells. These cells can recognize and kill cancer cells and can form an immunological memory. Dendritic cells (DCs) are the professional antigen-presenting cells of our immune system. They take up and process antigens to present them to T cells. Consequently, DCs have been investigated as a means to stimulate cancer-specific T-cell responses. An efficient strategy to program DCs is the use of mRNA, a well-defined and safe molecule that can be easily generated at high purity. Importantly, vaccines consisting of mRNA-modified DCs showed promising results in clinical trials. Therefore, we will introduce cancer immunotherapy and DCs and give a detailed overview on the application of mRNA to generate cancer-fighting DC vaccines.

https://www.ncbi.nlm.nih.gov/pubmed/25196947

i dont think MRNA can deliver a better response over immunobody .. but maybe the cost of delivery is cheaper ..

but the only way to compare is a like for like trial .. ie same core antigens loaded

second that .. cheers

its panama7 ... he used to post on here .. now he just repeats the same crap every week or so ...on ADFVN ...

Bermuda

containment ?

40 epitopes would keep BioNtech busy for years ..

the interesting hypothesis is BioNtech and Genetech screening individuals for specific Citrullinated and homocitrullinated epitopes .... thus the building of a 40 epitope "Viral bank" adds a second positive ... in that you can add Viral vectors to suit

you see Modi1 would in effect create ""3 CD4 t cells "".. one for each of the epitopes ...

I would assume the HSE involvement revolves around "contamination" getting the process from human patient blood extraction to product re -infusion spot on ... specifically the addition of "differentiation" to the usual BioNtech process has to be considered but i am stabbing in the dark ..

well it is a deal ... they have signed up to the collaboration which in itself is a deal ...

? TCR
? Project delayed due to requirement for Health and Safety Approval (HSE)
? Lenti-viral transduction of T cells now working in the lab
? 40 TCRs recognising citrullinated/homocitrullinated epitopes to screen

40 !!! wow

https://www.scancell.co.uk/Data/Sites/1/media/docspres/agm-2019_all_09sep19.pdf

Rats .... can he be an underwater drip ?

Scancell is all about the Jab ... knowlesi .. the boys have 6 to 7 year exp.

I have been saying it for 6 years ... well done 2Cv ...